002675 东诚药业
已收盘 10-23 15:00:00
资讯
新帖
简况
东诚药业（002675）10月22日主力资金净卖出132.65万元
证券之星 · 10-23 09:07
东诚药业（002675）10月22日主力资金净卖出132.65万元
东诚药业（002675）10月15日主力资金净买入69.55万元
证券之星 · 10-16
东诚药业（002675）10月15日主力资金净买入69.55万元
股市必读：东诚药业新发布《第六届董事会第二十二次会议决议公告》
证券之星 · 10-16
股市必读：东诚药业新发布《第六届董事会第二十二次会议决议公告》
10月15日东诚药业跌8.51%，银河医药混合A基金重仓该股
证券之星 · 10-15
10月15日东诚药业跌8.51%，银河医药混合A基金重仓该股
东诚药业（002675）10月14日主力资金净买入1918.45万元
证券之星 · 10-15
东诚药业（002675）10月14日主力资金净买入1918.45万元
股市必读：东诚药业新发布《第六届董事会第二十二次会议决议公告》
证券之星 · 10-15
股市必读：东诚药业新发布《第六届董事会第二十二次会议决议公告》
东诚药业最新公告：终止分拆子公司蓝纳成至香港联交所主板上市
证券之星 · 10-14
东诚药业最新公告：终止分拆子公司蓝纳成至香港联交所主板上市
东诚药业：拟不超11.21亿元回购控股子公司蓝纳成少数股东股权
格隆汇 · 10-14
东诚药业：拟不超11.21亿元回购控股子公司蓝纳成少数股东股权
东诚药业：终止分拆蓝纳成上市 承诺一个月内不再筹划重组
格隆汇 · 10-14
东诚药业：终止分拆蓝纳成上市 承诺一个月内不再筹划重组
东诚药业（002675）10月9日主力资金净买入1.27亿元
证券之星 · 10-12
东诚药业（002675）10月9日主力资金净买入1.27亿元
10月9日东诚药业涨9.98%，银河医药混合A基金重仓该股
证券之星 · 10-09
10月9日东诚药业涨9.98%，银河医药混合A基金重仓该股
异动快报：东诚药业（002675）10月9日10点36分触及涨停板
证券之星 · 10-09
异动快报：东诚药业（002675）10月9日10点36分触及涨停板
东诚药业（002675）披露回购公司股份进展情况的公告，10月8日股价下跌2.09%
证券之星 · 10-08
东诚药业（002675）披露回购公司股份进展情况的公告，10月8日股价下跌2.09%
公司问答丨东诚药业：核医学在精准治疗和肿瘤诊疗一体化方面具有无可比拟的优势
格隆汇 · 09-14
公司问答丨东诚药业：核医学在精准治疗和肿瘤诊疗一体化方面具有无可比拟的优势
股市必读：东诚药业新发布《关于子公司首次通过美国FDA现场检查的公告》
证券之星 · 09-14
股市必读：东诚药业新发布《关于子公司首次通过美国FDA现场检查的公告》
东诚药业：子公司首次通过美国FDA现场检查
格隆汇 · 09-11
东诚药业：子公司首次通过美国FDA现场检查
东诚药业最新公告：贝米肝素钠注射液上市申请获国家药监局受理
证券之星 · 09-09
东诚药业最新公告：贝米肝素钠注射液上市申请获国家药监局受理
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
证券之星 · 09-04
股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》
东诚药业（002675）披露回购公司股份进展情况公告，9月2日股价下跌1.22%
证券之星 · 09-02
东诚药业（002675）披露回购公司股份进展情况公告，9月2日股价下跌1.22%
股市必读：东诚药业新发布《关于全资子公司购买和转让下属公司股权的公告》
证券之星 · 08-26
股市必读：东诚药业新发布《关于全资子公司购买和转让下属公司股权的公告》
公司概况
公司名称：
烟台东诚药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-05-25
主营业务：
烟台东诚药业集团股份有限公司的主营业务是核医药业务、化药业务。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。
发行价格：
26.00
{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":13.4,"timestamp":1792739016000,"preClose":13.13,"halted":0,"volume":11491080,"delay":0,"changeRate":0.0206,"floatShares":743000000,"shares":825000000,"eps":0.2435,"marketStatus":"已收盘","change":0.27,"latestTime":"10-23 15:00:00","open":13,"high":13.51,"low":13,"amount":153000000,"amplitude":0.0388,"askPrice":13.4,"askSize":34,"bidPrice":13.39,"bidSize":149,"shortable":0,"etf":0,"ttmEps":0.2435,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":13.13,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":14.44,"lowLimit":11.82,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.46,"roa":"--","peRate":55.030801,"roe":"2.16%","epsLYR":0.2372,"committee":-0.426916,"marketValue":11050000000,"turnoverRate":0.0155,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-26。","floatMarketCap":9961000000},"requestUrl":"/m/hq/s/002675/wiki","defaultTab":"wiki","newsList":[{"id":"2677791583","title":"东诚药业（002675）10月22日主力资金净卖出132.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677791583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677791583?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:07","pubTimestamp":1792717633,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月22日收盘，东诚药业报收于13.13元，上涨0.31%，换手率1.04%，成交量7.72万手，成交额1.02亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入379.61万元，融资偿还590.12万元，融资净偿还210.5万元。东诚药业主营业务：主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300009157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675655174","title":"东诚药业（002675）10月15日主力资金净买入69.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675655174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675655174?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:11","pubTimestamp":1792113079,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，东诚药业报收于12.69元，下跌8.51%，换手率3.85%，成交量28.59万手，成交额3.68亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入6065.81万元，融资偿还2345.81万元，融资净买入3720.0万元。东诚药业主营业务：主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675053228","title":"股市必读：东诚药业新发布《第六届董事会第二十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675053228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675053228?lang=zh_cn&edition=full","pubTime":"2026-10-16 03:27","pubTimestamp":1792092429,"startTime":"0","endTime":"0","summary":"关于终止分拆所属子公司至香港联合交易所有限公司主板上市的公告东诚药业于2026年10月13日召开第六届董事会第二十二次会议，审议通过终止分拆子公司烟台蓝纳成生物技术股份有限公司至香港联合交易所有限公司主板上市的议案，并撤回相关上市申请文件；终止原因为综合考量外部环境变化及公司与蓝纳成自身发展规划；本次终止不构成重大不利影响；公司承诺公告后一个月内不再筹划重大资产重组事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600004183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675302701","title":"10月15日东诚药业跌8.51%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675302701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675302701?lang=zh_cn&edition=full","pubTime":"2026-10-15 16:42","pubTimestamp":1792053734,"startTime":"0","endTime":"0","summary":"证券之星消息，10月15日东诚药业跌8.51%，收盘报12.69元，换手率3.85%，成交量28.59万手，成交额3.68亿元。银河医药混合A目前规模为3.51亿元，最新净值0.5513，较上一交易日下跌1.2%，近一年下跌7.45%。方伟在任的基金产品包括:银河康乐股票A，管理时间为2021年5月10日至今，期间收益率为-29.92%；银河医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500027662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675","BK1161","BK1515","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675376281","title":"东诚药业（002675）10月14日主力资金净买入1918.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675376281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675376281?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:05","pubTimestamp":1792026312,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月14日收盘，东诚药业报收于13.87元，上涨2.44%，换手率2.95%，成交量21.95万手，成交额3.04亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入1642.43万元，融资偿还1963.93万元，融资净偿还321.5万元。东诚药业主营业务：主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500007986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675809329","title":"股市必读：东诚药业新发布《第六届董事会第二十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675809329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675809329?lang=zh_cn&edition=full","pubTime":"2026-10-15 01:00","pubTimestamp":1791997234,"startTime":"0","endTime":"0","summary":"公司公告汇总第六届董事会第二十二次会议决议公告2026年10月13日，东诚药业召开第六届董事会第二十二次会议，审议通过《关于终止分拆所属子公司至香港联合交易所主板上市的议案》；审议通过《关于购买控股子公司少数股东股权暨关联交易的议案》，关联董事回避表决，该议案尚需提交股东大会审议；审议通过《关于变更公司经营范围并修订〈公司章程〉的议案》及《关于提请召开2026年第二次临时股东会的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675349235","title":"东诚药业最新公告：终止分拆子公司蓝纳成至香港联交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2675349235","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675349235?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:50","pubTimestamp":1791978628,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，基于外部环境变化及自身发展规划考量，决定终止分拆所属子公司蓝纳成至香港联交所主板上市，并撤回相关申请文件。该事项已获董事会审议通过，无需提交股东会审议，不会对公司生产经营造成重大不利影响。公司承诺终止后一个月内不再筹划重大资产重组(含分拆上市)。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400035645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675349403","title":"东诚药业：拟不超11.21亿元回购控股子公司蓝纳成少数股东股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2675349403","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675349403?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:50","pubTimestamp":1791978606,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675349150","title":"东诚药业：终止分拆蓝纳成上市 承诺一个月内不再筹划重组","url":"https://stock-news.laohu8.com/highlight/detail?id=2675349150","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675349150?lang=zh_cn&edition=full","pubTime":"2026-10-14 19:46","pubTimestamp":1791978367,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674025842","title":"东诚药业（002675）10月9日主力资金净买入1.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674025842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674025842?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:03","pubTimestamp":1791767006,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月9日收盘，东诚药业报收于13.89元，上涨9.98%，涨停，换手率5.15%，成交量38.3万手，成交额5.19亿元。近5日资金流向一览见下表：东诚药业融资融券信息显示，融资方面，当日融资买入3521.07万元，融资偿还3248.93万元，融资净买入272.14万元。东诚药业主营业务：主要业务分为原料药业务、制剂业务以及核医药业务三个板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200002782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674183215","title":"10月9日东诚药业涨9.98%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2674183215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674183215?lang=zh_cn&edition=full","pubTime":"2026-10-09 16:40","pubTimestamp":1791535211,"startTime":"0","endTime":"0","summary":"证券之星消息，10月9日东诚药业涨9.98%创60日新高，收盘报13.89元，换手率5.15%，成交量38.3万手，成交额5.19亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为银河基金的银河医药混合A。方伟在任的基金产品包括:银河康乐股票A，管理时间为2021年5月10日至今，期间收益率为-28.18%；银河医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900025747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK1161","BK1515","09939","BK1574","BK0239","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674788229","title":"异动快报：东诚药业（002675）10月9日10点36分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2674788229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674788229?lang=zh_cn&edition=full","pubTime":"2026-10-09 10:40","pubTimestamp":1791513642,"startTime":"0","endTime":"0","summary":"证券之星10月9日盘中消息，10点36分东诚药业（002675）触及涨停板。其所属行业化学制药目前下跌。领涨股为向日葵。该股为肝素，幽门螺杆菌概念，PD-1抑制剂概念热股，当日肝素概念上涨1.34%，幽门螺杆菌概念概念上涨0.22%，PD-1抑制剂概念上涨0.1%。10月8日的资金流向数据方面，主力资金净流入216.11万元，占总成交额1.94%，游资资金净流入587.71万元，占总成交额5.29%，散户资金净流出803.81万元，占总成交额7.23%。近5日资金流向一览见下表：东诚药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900011921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673005614","title":"东诚药业（002675）披露回购公司股份进展情况的公告，10月8日股价下跌2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673005614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673005614?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:43","pubTimestamp":1791470592,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，东诚药业报收于12.63元，较前一交易日下跌2.09%，最新总市值为104.15亿元。该股当日开盘13.0元，最高13.13元，最低12.6元，成交额达1.11亿元，换手率为1.18%。近日，烟台东诚药业集团股份有限公司发布《关于回购公司股份进展情况的公告》。回购符合相关法规及公司既定方案。公司严格遵守回购期间相关监管要求，未在禁止期间回购股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800034802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659576","title":"公司问答丨东诚药业：核医学在精准治疗和肿瘤诊疗一体化方面具有无可比拟的优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659576","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659576?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:26","pubTimestamp":1789374388,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667680042","title":"股市必读：东诚药业新发布《关于子公司首次通过美国FDA现场检查的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2667680042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667680042?lang=zh_cn&edition=full","pubTime":"2026-09-14 02:47","pubTimestamp":1789325231,"startTime":"0","endTime":"0","summary":"公司公告汇总：控股子公司中泰生物于2026年7月17–18日通过美国FDA现场检查，获NAI结论，未发现483缺陷。公司公告汇总关于子公司首次通过美国FDA现场检查的公告烟台东诚药业集团股份有限公司控股子公司Sino Siam Biotechnique Company Limited于2026年7月17日至7月18日接受美国FDA现场检查，检查范围为硫酸软骨素钠原料生产，依据美国21CFR第117部分进行；近日收到FDA签发的现场检查报告，检查结果为NAI，未发现483缺陷。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400001112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666352181","title":"东诚药业：子公司首次通过美国FDA现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2666352181","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666352181?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:34","pubTimestamp":1789126471,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666264582","title":"东诚药业最新公告：贝米肝素钠注射液上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666264582","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666264582?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:50","pubTimestamp":1788951042,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司全资子公司东诚北方收到国家药品监督管理局核准签发的关于贝米肝素钠注射液上市许可申请的《受理通知书》。该药品为一种低分子量肝素，适用于血液透析时预防体外循环中发生凝血，以及预防普外手术和骨科手术患者的血栓栓塞性疾病。目前该产品国内仅原研上市，无仿制药上市，2025年国内全终端医院销售额为3亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900033589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664068658","title":"股市必读：东诚药业新发布《关于回购公司股份进展情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664068658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664068658?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:47","pubTimestamp":1788457632,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘，东诚药业报收于12.87元，下跌0.54%，换手率0.44%，成交量3.24万手，成交额4177.34万元。公司公告汇总：截至2026年8月31日，东诚药业已回购股份7,399,499股，占总股本0.90%，支付资金总额100,168,758.70元。公司公告汇总关于回购公司股份进展情况的公告烟台东诚药业集团股份有限公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810173","title":"东诚药业（002675）披露回购公司股份进展情况公告，9月2日股价下跌1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810173?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:55","pubTimestamp":1788360912,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，东诚药业报收于12.94元，较前一交易日下跌1.22%，最新总市值为106.7亿元。该股当日开盘13.04元，最高13.1元，最低12.91元，成交额达6372.92万元，换手率为0.66%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。公告显示，公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。回购进展符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662757517","title":"股市必读：东诚药业新发布《关于全资子公司购买和转让下属公司股权的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662757517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662757517?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:28","pubTimestamp":1787693296,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，东诚药业报收于12.96元，上涨1.49%，换手率0.74%，成交量5.54万手，成交额7144.59万元。公司公告汇总关于全资子公司购买和转让下属公司股权的公告东诚药业全资子公司安迪科以4,020万元向广东回旋购买昆明回旋100%股权，以4,000万元购买四川回旋100%股权，并以121,454,650.80元向高尚医药出售广东回旋45%股份。本次交易不构成关联交易，亦不构成重大资产重组，已在公司总经理审批权限内，无需提交董事会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600008475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792910816804,"stockEarnings":[{"period":"1week","weight":0.0585},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0815},{"period":"6month","weight":-0.0051},{"period":"1year","weight":-0.0671},{"period":"ytd","weight":-0.0189}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29858人(较上一季度减少24.50%)","perCapita":"24897股","listingDate":"2012-05-25","address":"山东省烟台市福山区烟台经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":" 烟台东诚药业集团股份有限公司的主营业务是核医药业务、化药业务。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}